View ValuationSynCore BiotechnologyLtd 将来の成長Future 基準チェック /06現在、 SynCore BiotechnologyLtdの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長15.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 16First quarter 2026 earnings released: NT$0.37 loss per share (vs NT$0.39 loss in 1Q 2025)First quarter 2026 results: NT$0.37 loss per share (improved from NT$0.39 loss in 1Q 2025). Revenue: NT$6.12m (up 14% from 1Q 2025). Net loss: NT$13.0m (loss narrowed 5.0% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 14Full year 2025 earnings released: NT$1.30 loss per share (vs NT$1.54 loss in FY 2024)Full year 2025 results: NT$1.30 loss per share (improved from NT$1.54 loss in FY 2024). Revenue: NT$27.0m (up 16% from FY 2024). Net loss: NT$45.8m (loss narrowed 16% from FY 2024). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.お知らせ • Mar 11SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 17, 2026SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 17, 2026. Location: no,95, hsin liao rd., chung shan ts`u, dongshan township, yilan county TaiwanReported Earnings • Nov 19Third quarter 2025 earnings released: NT$0.23 loss per share (vs NT$0.41 loss in 3Q 2024)Third quarter 2025 results: NT$0.23 loss per share (improved from NT$0.41 loss in 3Q 2024). Revenue: NT$6.47m (up 22% from 3Q 2024). Net loss: NT$8.04m (loss narrowed 44% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$0.33 loss per share (vs NT$0.38 loss in 2Q 2024)Second quarter 2025 results: NT$0.33 loss per share (improved from NT$0.38 loss in 2Q 2024). Revenue: NT$7.82m (up 10% from 2Q 2024). Net loss: NT$11.7m (loss narrowed 13% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Reported Earnings • May 18First quarter 2025 earnings released: NT$0.39 loss per share (vs NT$0.38 loss in 1Q 2024)First quarter 2025 results: NT$0.39 loss per share (further deteriorated from NT$0.38 loss in 1Q 2024). Revenue: NT$5.39m (up 23% from 1Q 2024). Net loss: NT$13.7m (loss widened 2.1% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.お知らせ • Feb 27SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 20, 2025SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 20, 2025. Location: no,95, hsin liao rd., chung shan ts`u, dongshan township, yilan county TaiwanReported Earnings • Aug 18Second quarter 2024 earnings released: NT$0.38 loss per share (vs NT$0.86 loss in 2Q 2023)Second quarter 2024 results: NT$0.38 loss per share (improved from NT$0.86 loss in 2Q 2023). Net loss: NT$13.5m (loss narrowed 49% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.New Risk • Apr 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$20m revenue, or US$631k). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (NT$1.95b market cap, or US$61.0m).お知らせ • Mar 27SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 18, 2024SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 18, 2024.Reported Earnings • Mar 21Full year 2023 earnings released: NT$1.19 loss per share (vs NT$6.14 loss in FY 2022)Full year 2023 results: NT$1.19 loss per share (improved from NT$6.14 loss in FY 2022). Net loss: NT$38.2m (loss narrowed 80% from FY 2022). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.New Risk • Nov 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$18m revenue, or US$555k). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (NT$1.24b market cap, or US$38.8m).New Risk • Jul 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 274% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (274% increase in shares outstanding). Revenue is less than US$1m (NT$16m revenue, or US$520k).Reported Earnings • Mar 09Full year 2022 earnings released: NT$1.64 loss per share (vs NT$4.04 loss in FY 2021)Full year 2022 results: NT$1.64 loss per share (improved from NT$4.04 loss in FY 2021). Net loss: NT$188.7m (loss narrowed 59% from FY 2021). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 7 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Fu-Hsing Chang was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Aug 16Second quarter 2022 earnings released: NT$0.30 loss per share (vs NT$0.77 loss in 2Q 2021)Second quarter 2022 results: NT$0.30 loss per share (up from NT$0.77 loss in 2Q 2021). Net loss: NT$34.0m (loss narrowed 62% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 7 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Fu-Hsing Chang was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 13Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: NT$4.04 loss per share (down from NT$3.83 loss in FY 2020). Net loss: NT$458.6m (loss widened 15% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 7% per year.Reported Earnings • Nov 15Third quarter 2021 earnings released: NT$1.90 loss per share (vs NT$0.96 loss in 3Q 2020)Third quarter 2021 results: Net loss: NT$218.7m (loss widened 114% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 13Second quarter 2021 earnings released: NT$0.77 loss per share (vs NT$1.08 loss in 2Q 2020)Second quarter 2021 results: Net loss: NT$88.2m (loss narrowed 20% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 16First quarter 2021 earnings released: NT$0.65 loss per share (vs NT$0.87 loss in 1Q 2020)First quarter 2021 results: Net loss: NT$71.6m (loss narrowed 15% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.Reported Earnings • Mar 24Full year 2020 earnings released: NT$3.83 loss per share (vs NT$4.54 loss in FY 2019)Full year 2020 results: Net loss: NT$398.9m (loss narrowed 2.4% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.分析記事 • Mar 01Health Check: How Prudently Does SynCore BiotechnologyLtd (GTSM:4192) Use Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Is New 90 Day High Low • Feb 23New 90-day high: NT$54.30The company is up 11% from its price of NT$48.70 on 25 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 7.0% over the same period.Is New 90 Day High Low • Jan 29New 90-day low: NT$39.95The company is down 17% from its price of NT$48.30 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 16% over the same period.Is New 90 Day High Low • Jan 11New 90-day low: NT$44.10The company is down 21% from its price of NT$55.90 on 14 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 15% over the same period.Reported Earnings • Nov 14Third quarter 2020 earnings released: NT$0.96 loss per shareThird quarter 2020 results: Net loss: NT$102.0m (loss narrowed 7.9% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Oct 31New 90-day low: NT$48.30The company is down 33% from its price of NT$72.20 on 31 July 2020. The Taiwanese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.Is New 90 Day High Low • Oct 08New 90-day low: NT$58.20The company is down 58% from its price of NT$137 on 10 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 25% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、SynCore BiotechnologyLtd は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TPEX:4192 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202628-45-32-31N/A12/31/202527-46-39-38N/A9/30/202526-46-30-30N/A6/30/202525-53-36-35N/A3/31/202524-55-42-42N/A12/31/202423-54-50-49N/A9/30/2024230-77-76N/A6/30/202423-15-78-78N/A3/31/202421-28-75-75N/A12/31/202320-38-83-82N/A9/30/202319-162-69-68N/A6/30/202318-163-104-103N/A3/31/202316-170-173-172N/A12/31/202216-189-211-210N/A9/30/202214-187-250-249N/A6/30/202211-375-252-251N/A3/31/20229-429-233-232N/A12/31/20217-459-231-230N/A9/30/202110-481-251-245N/A6/30/202112-364-278-272N/A3/31/202113-386-284-278N/A12/31/202013-399-323-317N/A9/30/202010-409-398-397N/A6/30/20208-417-422-420N/A3/31/20209-430-445-441N/A12/31/201913-409N/A-419N/A9/30/201913-389N/A-359N/A6/30/201913-359N/A-337N/A3/31/201912-306N/A-305N/A12/31/20188-294N/A-272N/A9/30/20188-270N/A-229N/A6/30/20188-253N/A-197N/A3/31/20188-247N/A-184N/A12/31/20178-258N/A-202N/A9/30/20178-186N/A-218N/A6/30/20178-177N/A-220N/A3/31/20177-176N/A-225N/A12/31/20167-162N/A-195N/A9/30/20167-185N/A-153N/A6/30/20167-201N/A-154N/A3/31/201616-179N/A-152N/A12/31/201515-182N/A-156N/A9/30/201515-223N/A-204N/A6/30/201515-223N/A-220N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 4192の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 4192の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 4192の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 4192の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 4192の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 4192の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 11:47終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SynCore Biotechnology Co.,Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 16First quarter 2026 earnings released: NT$0.37 loss per share (vs NT$0.39 loss in 1Q 2025)First quarter 2026 results: NT$0.37 loss per share (improved from NT$0.39 loss in 1Q 2025). Revenue: NT$6.12m (up 14% from 1Q 2025). Net loss: NT$13.0m (loss narrowed 5.0% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 14Full year 2025 earnings released: NT$1.30 loss per share (vs NT$1.54 loss in FY 2024)Full year 2025 results: NT$1.30 loss per share (improved from NT$1.54 loss in FY 2024). Revenue: NT$27.0m (up 16% from FY 2024). Net loss: NT$45.8m (loss narrowed 16% from FY 2024). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
お知らせ • Mar 11SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 17, 2026SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 17, 2026. Location: no,95, hsin liao rd., chung shan ts`u, dongshan township, yilan county Taiwan
Reported Earnings • Nov 19Third quarter 2025 earnings released: NT$0.23 loss per share (vs NT$0.41 loss in 3Q 2024)Third quarter 2025 results: NT$0.23 loss per share (improved from NT$0.41 loss in 3Q 2024). Revenue: NT$6.47m (up 22% from 3Q 2024). Net loss: NT$8.04m (loss narrowed 44% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$0.33 loss per share (vs NT$0.38 loss in 2Q 2024)Second quarter 2025 results: NT$0.33 loss per share (improved from NT$0.38 loss in 2Q 2024). Revenue: NT$7.82m (up 10% from 2Q 2024). Net loss: NT$11.7m (loss narrowed 13% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Reported Earnings • May 18First quarter 2025 earnings released: NT$0.39 loss per share (vs NT$0.38 loss in 1Q 2024)First quarter 2025 results: NT$0.39 loss per share (further deteriorated from NT$0.38 loss in 1Q 2024). Revenue: NT$5.39m (up 23% from 1Q 2024). Net loss: NT$13.7m (loss widened 2.1% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
お知らせ • Feb 27SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 20, 2025SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 20, 2025. Location: no,95, hsin liao rd., chung shan ts`u, dongshan township, yilan county Taiwan
Reported Earnings • Aug 18Second quarter 2024 earnings released: NT$0.38 loss per share (vs NT$0.86 loss in 2Q 2023)Second quarter 2024 results: NT$0.38 loss per share (improved from NT$0.86 loss in 2Q 2023). Net loss: NT$13.5m (loss narrowed 49% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
New Risk • Apr 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$20m revenue, or US$631k). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (NT$1.95b market cap, or US$61.0m).
お知らせ • Mar 27SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 18, 2024SynCore Biotechnology Co.,Ltd, Annual General Meeting, Jun 18, 2024.
Reported Earnings • Mar 21Full year 2023 earnings released: NT$1.19 loss per share (vs NT$6.14 loss in FY 2022)Full year 2023 results: NT$1.19 loss per share (improved from NT$6.14 loss in FY 2022). Net loss: NT$38.2m (loss narrowed 80% from FY 2022). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
New Risk • Nov 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$18m revenue, or US$555k). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (NT$1.24b market cap, or US$38.8m).
New Risk • Jul 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 274% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (274% increase in shares outstanding). Revenue is less than US$1m (NT$16m revenue, or US$520k).
Reported Earnings • Mar 09Full year 2022 earnings released: NT$1.64 loss per share (vs NT$4.04 loss in FY 2021)Full year 2022 results: NT$1.64 loss per share (improved from NT$4.04 loss in FY 2021). Net loss: NT$188.7m (loss narrowed 59% from FY 2021). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 7 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Fu-Hsing Chang was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 16Second quarter 2022 earnings released: NT$0.30 loss per share (vs NT$0.77 loss in 2Q 2021)Second quarter 2022 results: NT$0.30 loss per share (up from NT$0.77 loss in 2Q 2021). Net loss: NT$34.0m (loss narrowed 62% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 7 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Fu-Hsing Chang was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 13Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: NT$4.04 loss per share (down from NT$3.83 loss in FY 2020). Net loss: NT$458.6m (loss widened 15% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 7% per year.
Reported Earnings • Nov 15Third quarter 2021 earnings released: NT$1.90 loss per share (vs NT$0.96 loss in 3Q 2020)Third quarter 2021 results: Net loss: NT$218.7m (loss widened 114% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 13Second quarter 2021 earnings released: NT$0.77 loss per share (vs NT$1.08 loss in 2Q 2020)Second quarter 2021 results: Net loss: NT$88.2m (loss narrowed 20% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 16First quarter 2021 earnings released: NT$0.65 loss per share (vs NT$0.87 loss in 1Q 2020)First quarter 2021 results: Net loss: NT$71.6m (loss narrowed 15% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 24Full year 2020 earnings released: NT$3.83 loss per share (vs NT$4.54 loss in FY 2019)Full year 2020 results: Net loss: NT$398.9m (loss narrowed 2.4% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.
分析記事 • Mar 01Health Check: How Prudently Does SynCore BiotechnologyLtd (GTSM:4192) Use Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Is New 90 Day High Low • Feb 23New 90-day high: NT$54.30The company is up 11% from its price of NT$48.70 on 25 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 7.0% over the same period.
Is New 90 Day High Low • Jan 29New 90-day low: NT$39.95The company is down 17% from its price of NT$48.30 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 16% over the same period.
Is New 90 Day High Low • Jan 11New 90-day low: NT$44.10The company is down 21% from its price of NT$55.90 on 14 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 15% over the same period.
Reported Earnings • Nov 14Third quarter 2020 earnings released: NT$0.96 loss per shareThird quarter 2020 results: Net loss: NT$102.0m (loss narrowed 7.9% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Oct 31New 90-day low: NT$48.30The company is down 33% from its price of NT$72.20 on 31 July 2020. The Taiwanese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Oct 08New 90-day low: NT$58.20The company is down 58% from its price of NT$137 on 10 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 25% over the same period.